uniQure N.V. - Ordinary Shares (QURE) News

uniQure N.V. - Ordinary Shares (QURE): $13.84

0.48 (+3.59%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add QURE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 393

in industry

Filter QURE News Items

QURE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

QURE News Highlights

  • For QURE, its 30 day story count is now at 5.
  • Over the past 10 days, the trend for QURE's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • GENE, AMT and CBRE are the most mentioned tickers in articles about QURE.

Latest QURE News From Around the Web

Below are the latest news stories about uniQure NV that investors may wish to consider to help them evaluate QURE as an investment opportunity.

uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington''s Disease

LEXINGTON, Mass. and AMSTERDAM, Feb. 07, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE ), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the dosing of the first two patients in its European open-label Phase Ib/II clinical trial of AMT-130, a potential one-time gene-therapy approach for the treatment of Huntington''s disease. The clinical trial is taking place at several sites in Poland, the United Kingdom and Germany. "We are very pleased to expand the clinical development of AMT-130 and to build on our ongoing experience in the Phase I/II clinical trial in the United States," stated Ricardo Dolmetsch, Ph.D., president of research and development at uniQure. "We expect to complete patient enrollment in this...

Benzinga | February 7, 2022

uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease

LEXINGTON, Mass. and AMSTERDAM, Feb. 07, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the dosing of the first two patients in its European open-label Phase Ib/II clinical trial of AMT-130, a potential one-time gene-therapy approach for the treatment of Huntington’s disease. The clinical trial is taking place at several sites in Poland, the United Kingdom and Germany.

GlobeNewswire | February 7, 2022

Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B - Data Presented at EAHAD 2022

Global biotherapeutics leader CSL Behring today announced positive long-term results from the Phase 3 HOPE-B clinical trial evaluating etranacogene dezaparvovec (EtranaDez), an investigational adeno-associated virus five (AAV5)-based gene therapy for people living with hemophilia B, a life-threatening bleeding disorder. Following a single infusion of etranacogene dezaparvovec, participants experienced a stable and durable increase in mean Factor IX (FIX) activity and hemostatic protection at 18

Yahoo | February 4, 2022

Everence Capital Management Inc Buys LyondellBasell Industries NV, Colgate-Palmolive Co, Match ...

Goshen, IN, based Investment company Everence Capital Management Inc (Current Portfolio) buys LyondellBasell Industries NV, Colgate-Palmolive Co, Match Group Inc, Activision Blizzard Inc, Merck Inc, sells CBRE Group Inc, JPMorgan Chase, Johnson Controls International PLC, The Estee Lauder Inc, Republic Services Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Everence Capital Management Inc.

Yahoo | January 28, 2022

Top Biotech Stocks for Q1 2022

The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline.

Yahoo | January 18, 2022

uniQure N.V.'s (NASDAQ:QURE) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

uniQure (NASDAQ:QURE) has had a rough three months with its share price down 29%. However, stock prices are usually...

Yahoo | January 17, 2022

Is Uniqure NV (QURE) A Good Stock To Buy?

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 900 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]

Yahoo | January 12, 2022

After Plunging 33.5% in 4 Weeks, Here''s Why the Trend Might Reverse for uniQure (QURE)

The heavy selling pressure might have exhausted for uniQure (QURE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts

Entrepreneur | January 6, 2022

After Plunging 33.5% in 4 Weeks, Here's Why the Trend Might Reverse for uniQure (QURE)

The heavy selling pressure might have exhausted for uniQure (QURE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Yahoo | January 6, 2022

uniQure (QURE) Upgraded to Buy: Here's Why

uniQure (QURE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | December 31, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4659 seconds.